Since the AKT/mTOR pathway is a key mechanism for gemcitabine resistance in pancreatic cancer cells, this study demonstrated that harmine and gemcitabine, in combination, significantly suppressed the AKT/mTOR signaling pathway. This evidence concerns the gene AKT1 and pancreatic neoplasm.